Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 14, 2023 | -$0.57 | -$0.44 | Beat |
| Aug 14, 2023 | -$0.60 | -$0.59 | Beat |
| May 10, 2023 | -$0.60 | -$0.60 | Beat |
| Mar 30, 2023 | -$0.58 | -$0.59 | Miss |
| Nov 14, 2022 | -$0.57 | -$0.55 | Beat |
| Aug 15, 2022 | -$0.55 | -$0.57 | Miss |